You are here

Article Text

Article menu
Letters to the editor
Montelukast sodium in cystic fibrosis
Free
  1. A H MORICE,
  2. J A KASTELIK,
  3. I AZIZ
  1. Academic Department of Medicine
  2. University of Hull
  3. Castle Hill Hospital
  4. Cottingham
  5. East Yorkshire HU16 5JQ, UK
  6. a.h.morice@medschool.hull.ac.uk
  1. Professor A H Morice

https://doi.org/10.1136/thorax.56.3.244a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Many older patients with cystic fibrosis (CF) describe a component of their condition as “asthma” despite a lack of objective bronchial lability. We undertook a therapeutic trial of the leukotriene antagonist montelukast sodium in one such patient and observed a marked improvement in symptoms and peak expiratory flow rate (PEFR). Subsequently we performed an open label study in adult patients attending the Hull Adult Cystic Fibrosis Clinic.

    Eleven patients (eight male) of mean (range) age 25.9 (16–44) years with stable CF and no pulmonary infective exacerbations for at least four weeks entered a two week observation period during which they recorded a …

    View Full Text